All In Biotech

Drug Trial Radar · NCT07843940

A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)

A Phase Ib/II, Open-label, Safety and Tolerability Trial of Intravenous Obrixtamig in Combination With Pumitamig and Standard of Care (Carboplatin, Etoposide) in Patients With Extensive-stage Small Cell Lung Carcinoma

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

55

Planned (sponsor's estimate)

Start

Oct 1, 2026

Primary completion

Apr 17, 2030

Study completion Apr 21, 2030

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
Collaborators
BioNTech SE
First posted
Sep 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults with extensive-stage small cell lung cancer. The purpose of this study is to find out how well people with this type of cancer tolerate taking study medicines called obrixtamig and pumitamig. Another purpose is to check whether the combination study treatment can make tumours shrink. Obrixtamig and pumitamig are being developed to help the immune system fight cancer. Participants are put into 2 groups. One group gets obrixtamig and pumitamig. The other group gets obrixtamig and pumitamig with standard chemotherapy (carboplatin and etoposide). All study treatments are given as infusions into a vein. This study does not have a fixed duration. Participants can receive obrixtamig and pumitamig for up to 2 years if they benefit from treatment and can tolerate it. Participants visit the study site regularly, with some overnight stays required. During this time, doctors regularly check for health problems that could be caused by the study treatment. They also monitor the size of the tumour(s) and take laboratory tests.

Conditions

  • Extensive-stage Small Cell Lung Carcinoma
  • Advanced Small Cell Lung Cancer

Interventions

  • ObrixtamigDrug

    Obrixtamig

  • PumitamigDrug

    Pumitamig

  • CarboplatinDrug

    Carboplatin

  • EtoposideDrug

    Etoposide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of treatment-emergent adverse events (AEs) leading to trial medication discontinuation or dose modificationTime frame: up to 27 months

Locations

27 sites in 10 countries. Site status is shown where the registry gives one.

  • University of Miami

    Miami, Florida · Not yet recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Not yet recruiting

  • START New Jersey

    East Brunswick, New Jersey · Recruiting

  • New York University Langone Medical Center

    New York, New York · Not yet recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Not yet recruiting

  • Chris Obrien Lifehouse

    Camperdown, New South Wales, Australia · Not yet recruiting

  • Townsville University Hospital

    Douglas, Queensland, Australia · Not yet recruiting

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium · Not yet recruiting

  • Universitair Ziekenhuis Gent

    Ghent, Belgium · Not yet recruiting

  • Sichuan Cancer Hospital

    Chengdu, China · Not yet recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, China · Not yet recruiting

  • Shanghai Chest Hospital

    Shanghai, China · Not yet recruiting

  • CTR Leon Berard

    Lyon, France · Not yet recruiting

  • HOP Timone

    Marseille, France · Not yet recruiting

  • Institut Gustave Roussy

    Villejuif, France · Not yet recruiting

  • Technische Universität Dresden

    Dresden, Germany · Not yet recruiting

  • Universitätsklinikum Essen AöR

    Essen, Germany · Not yet recruiting

  • Universitätsklinikum Tübingen

    Tübingen, Germany · Not yet recruiting

  • Okayama University Hospital

    Okayama, Okayama, Japan · Not yet recruiting

  • Kansai Medical University Hospital

    Osaka, Hirakata, Japan · Not yet recruiting

  • Shizuoka Cancer Center

    Shizuoka, Sunto-gun, Japan · Not yet recruiting

  • Universitair Medisch Centrum Groningen

    Groningen, Netherlands · Not yet recruiting

  • Szpital Specjalistyczny W Brzozowie Podkarpacki Osrodek Onkologiczny Im.Ks.B.Markiewicza

    Brzozów, Poland · Not yet recruiting

  • Lower Silesian Oncology Centre

    Wroclaw, Poland · Not yet recruiting

  • Hospital Clínic de Barcelona

    Barcelona, Spain · Not yet recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Spain · Not yet recruiting

  • Hospital Clinico De Valencia (INCLIVA)

    Valencia, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.